After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial
MacroGenics Inc. (NASDAQ:MGNX) announced on Tuesday that it reviewed data accumulated from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo).
In May, when the company released interim data from the trial, MacroGenics reported five deaths (fatal outcome) during the trial.
After reviewing, MacroGenics agreed with the study’s Independent Data Monitoring Committee’s recommendation to discontinue the treatment for the remaining metastatic castration-resistant prostate cancer (mCRPC) study participants who could have received additional doses.
Most of these remaining study participants had already received 8-12 cycles of vobra duo. Participants continue to be monitored for adverse events, disease progression and survival.
“We decided to discontinue additional dosing for the remaining TAMARACK participants who had not yet completed treatment. We expect to have the data necessary to determine next steps for the vobra duo program later this year and will provide further updates on an investor call …
Full story available on Benzinga.com